Objective:
To expand procedural services and integrate advanced therapeutic technologies into clinical practice for eye care professionals, as stated by Lumenis.
Key Findings:
- The program supports clinicians in diversifying revenue and reducing reliance on traditional reimbursement, as stated by Lumenis.
- Accelerate features perspectives from leading practitioners and interactive training with Lumenis technologies.
- OptiLIGHT is the first FDA-approved IPL device for dry eye management, according to Lumenis.
Interpretation:
Limitations:
- Details on future dates and locations are yet to be announced, as mentioned by Lumenis.
Conclusion:
The 2026 Accelerate education series emphasizes peer learning and the integration of advanced technologies in eye care, as outlined by Lumenis.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
